A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

Inclusion Criteria: * Biopsy proven systemic AL amyloidosis. * Cardiac involvement with septum thickness more than 12 mm (without other causes as published by Gertz et al., hypertension or other potential causes of left ventricular hypertrophy) * Previously treated with chemotherapy, induced at least a very good partial remission of the underlying monoclonal plasma cell or B cell disorder. * GPT and GOT less than 3-times ULN. * Life expectancy more than 12 month. * Ability of subject to understand character and individual consequences of the clinical trail. * Written informed consent. * For women with childbearing potential and men, adequate contraception. Exclusion Criteria: * Age less than 18 years. * Concomitant multiple myeloma stage 2 and 3 (Salmon and Durie) * Concurrent chemotherapy necessary * Time to last chemotherapy more than 6 months. * Chronic liver disease, Bilirubin over 1,5 mg/dl * Not able to visit Amyloidosis Clinic in Heidelberg every 3 months. * History of hypersensitivity to the investigational product or to any substance with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * Participation in other clinical trials or observation period of competing trials, respectively. * Pregnant or nursing women.